Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome

Archives of Cardiovascular Diseases

Volumn 105, Issue 4, 2012, Pages 239-253

  Verges B ^a   Avignon, A ^b   Bonnet, F ^c   Catargi, B ^d   Cattan, S ^e   Cosson, E ^f   Ducrocq, G ^g   Elbaz, M ^h   Fredenrich, A ⁱ   Gourdy, P ^h   Henry, P ^j   Lairez, O ^h   Leguerrier, A M ^c   Monpere C ^k   Moulin, P ^l   Verges Patois B ^k   Roussel, R ^g   Steg, G ^g   Valensi, P ^f  

^a HÔPITAL DU BOCAGE   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e CHI de Le Raincy Montfermeil   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g BICHAT HOSPITAL   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j HÔPITAL LARIBOISIÈRE   (France)

^k Service de Réadaptation Cardiaque les Rosiers   (France)

^l HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

Acute coronary syndrome; Cardiology; Consensus; Diabetes; Hyperglycaemia; Review; Myocardial infarction

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; SULFONYLUREA; VALSARTAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONSENSUS; DIABETES MELLITUS; DIAGNOSTIC TEST; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART INFARCTION; HEART REHABILITATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; INSULIN INFUSION; INSULIN TREATMENT; INTENSIVE CARE UNIT; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PRACTICE GUIDELINE; SCREENING; STRESS; UNSPECIFIED SIDE EFFECT;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOLOGY; DIABETES MELLITUS; DIET; EVIDENCE-BASED MEDICINE; GLUCOSE TOLERANCE TEST; HEART FUNCTION TESTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTENSIVE CARE; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84861603278     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.01.008     Document Type: Article

References (120)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524. (Pubitemid 17050766)
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34. (Pubitemid 28350165)
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40. (Pubitemid 29056916)
4. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15-8. (Pubitemid 32066250)
5. Study Group DECODE, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
6. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4. (Pubitemid 34694020)
7. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004;164:1457-63. (Pubitemid 38937858)
8. Conaway DG, OKeefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005;96:363-5. (Pubitemid 41058859)
9. Vergès B, Zeller M, Dentan G, Beer JC, Laurent Y, Janin- Manificat, et al. Impact of fasting glycemia on short-term prognosis after acute myocardial infarction. J Clin Endocrinol Metab 2007;92:2136-40. (Pubitemid 46997112)
10. Les recommandations pour la pratique clinique - Base mé thodologique pour leur réalisation en France. http://www. has-sante.fr.
11. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117: 1018-27.
12. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005;111:3078-86. (Pubitemid 40847785)
13. Consultation WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report No. 99.2. Geneva: World Health Organization; 1999.
14. HAS (Haute Autorité de santé) Principes de dépistage du Diabete de type 2. Février 2003. http://www.has-sante.fr/ portail/upload/docs/application/pdf/diabete rap 2003.pdf.
15. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Hata T, et al. Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 2006;27:2413-9. (Pubitemid 44522147)
16. American Diabetes Association. Standards of Medical Care in Diabetes-2011: classification and diagnosis of diabetes. Diabetes Care 2011;34(Suppl. 1):S12.
17. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
18. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-90. (Pubitemid 39452604)
19. Wallander M, Malmberg K, Norhammar A, Rydén L, Tenerz A. Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 2008;31:36-8.
20. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, et al. Abnormal glucose tolerance-a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004;256:288-97. (Pubitemid 39304340)
21. Studygroup DECODE, the European diabetes epidemiology group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
22. Bartnik M, Rydén L, Malmberg K, Ohrvik J, Pyörälä K, Standl E, et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007;93: 72-7. (Pubitemid 46094058)
23. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010;42(Suppl. 1):S3-36.
24. Cosson E, Nguyen MT, Hamo-Tchatchouang E, Banu I, Chiheb S, Charnaux N, et al. What would be the outcome if the American Diabetes Association recommendations of 2010 had been followed in our practice in 1998-2006? Diabet Med 2011;28:567-74.
25. Kramer CK, Araneta MR, Barrett-Connor E. A1c and diabetes diagnosis: the Rancho Bernardo Study. Diabetes Care 2010;33:101-3.
26. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518-23.
27. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, et al. Abnormal glucose regulation in patients with acute ST-elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol 2009;8:6.
28. Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Rydén L, et al. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 2003;26:2770-6. (Pubitemid 37205545)
29. Malmberg K. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-5. (Pubitemid 27216066)
30. Weston C, Walker L, Birkhead J, National Audit of Myocardial Infarction Project, National Institute for Clinical Outcomes Research. Early impact of insulin treatment on mortality for hyperglycaemic patients without known diabetes who present with an acute coronary syndrome. Heart 2007;93: 1542-6. (Pubitemid 350205546)
31. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61. (Pubitemid 40516876)
32. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29:765-70. (Pubitemid 44115291)
33. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933-44.
34. Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 2006;55:3151-9. (Pubitemid 44923655)
35. Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997;14:648-54. (Pubitemid 27346853)
36. Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
37. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358: 125-39.
38. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-48.
39. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009;301:1556-64.
40. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care 2007;30:1005-11. (Pubitemid 46556604)
41. Prospective Diabetes Study (UKPDS) UK Group. UKPDS: effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
42. Bailey CJ. Metformin: effects on micro- and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008;22:215-24.
43. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-80.
44. Roussel R, Travert F, Pasquet B, Wilson PW, Smith Jr SC, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.
45. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008;29:166-76.
46. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011;54:1308-17.
47. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jrgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010;53:2546-53.
48. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl.):789-830.
49. Maruyama I, Tomiyama Y, Maruyama K, Ojima K, Kobayashi K, Kobayashi M, et al. Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Eur J Pharmacol 2006;531:194-200. (Pubitemid 43202235)
50. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
51. Prospective Diabetes UK Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
52. Collaborative ADVANCE Group. Effects of intensive blood glucose control on vascular outcomes in patients with type 2 diabetes mellitus: results of the ADVANCE trial. N Engl J Med 2008;358:2560-72.
53. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000;21:220-9. (Pubitemid 30137807)
54. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes Jr DR. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24. (Pubitemid 29064081)
55. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-84. (Pubitemid 47520905)
56. Arruda-Olson AM, Patch 3rd RK, Leibson CL, Vella A, Frye RL, Westaon SA, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009;84:28-33.
57. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95:4993-5002.
58. Horsdal HT, Johnsen SP, Sndergaard F, Jacobsen J, Thomsen RW, Schmitz O, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009;25:515-22.
59. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-8.
60. Study Group NAVIGATOR. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76.
61. Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alphaglucosidase inhibitor acarbose. FASEB J 2005;19:591-3. (Pubitemid 40471254)
62. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010;9:12.
63. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94. (Pubitemid 37430502)
64. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6. (Pubitemid 38055587)
65. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
66. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80. (Pubitemid 46629127)
67. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
68. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.
69. Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, et al. HDL-cholesterol and not HbA1c was directly related to Cardiovascular Outcome in PROactive. Diabetes Obes Metab 2011;13:759-64.
70. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51. (Pubitemid 40105106)
71. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-8. (Pubitemid 41698549)
72. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5. (Pubitemid 38282847)
73. Best JH, Rubin RR, Peyrot M, Li Y, Yan P, Malloy J, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucoselowering therapies. A retrospective analysis of the LifeLink database. Diabetes Care 2011;34:314-9.
74. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22.
75. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8:237-40.
76. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
77. Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, et al. Glucagon-like Peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764.
78. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
79. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94.
80. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122(3):16-27.
81. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35.
82. Piepoli MF, Corr U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1-17.
83. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801. (Pubitemid 34987553)
84. Vergès B, Patois-Vergès B, Cohen M, Lucas B, Galland-Jos C, Casillas JM. Effects of cardiac rehabilitation on exercise capacity, in type 2 diabetic patients with coronary artery disease. Diabet Med 2004;21:889-95. (Pubitemid 39037003)
85. Milani RV, Lavie CJ. Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. Am J Med 1996;100:517-23. (Pubitemid 26170475)
86. Joliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2002.
87. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;3:CD002968.
88. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-9. (Pubitemid 351697954)
89. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study 1. Diabetes 2005;54:158-65. (Pubitemid 40105108)
90. Praet SF, Van Loon U. Optimizing the therapeutic benefits of exercise in type 2 diabetes. J Appl Physiol 2007;103:1113-20. (Pubitemid 47605943)
91. Di LC, Fanelli C, Lucidi P, Murdolo G, De Cicco A, Parlanti N, et al. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care 2005;28:1295-302. (Pubitemid 40762631)
92. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev. Prediction of severe hypoglycemia. Diabetes Care 2007;30:1370-3.
93. Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton A, et al. Consensus statement on self-monitoring of blood glucose in diabetes. A European perspective. Diabetes Metab Heart 2009;18:285-9.
94. European guideline on cardiovascular disease prevention in clinical practice; Fourth joint Task Force of European and other societies. Eur J Cardiovasc Prev Rehab 2007;14(Suppl. 2):E1-40.
95. Vergès-Patois B, Vergès B. Nutrition counselling for diabetics patients. In: Perk J, Mathes P, Gohlke H, Monpère C, Hellemans I, McGee H, Sellier P, Saner H, editors. Textbook of cardiovascular prevention and rehabilitation. 2005.
96. Charbonnel B, Bouhanick B, Le Feuvre C, SFC/ALFEDIAM Groupe de travail. Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Arch Mal Coeur Vaiss 2004;97:229-49. (Pubitemid 38428776)
97. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9. (Pubitemid 24176333)
98. Franz MJ, Monk A, Barry B, McClain K, Weaver T, Cooper N, et al. Effectiveness of medical nutrition therapy provided by dieticians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc 1995;95:1009-17.
99. Hebert JR, Ebbeling CB, Ockene IS, Ma Y, Rider L, Merriam PA, et al. A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). J Am Diet Assoc 1999;99:544-52. (Pubitemid 29220377)
100. Delahanty LM, Sonnenberg LM, Hayden D, Nathan DM. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial. J Am Diet Assoc 2001;101:1012-23. (Pubitemid 33712393)
101. Powers MA, Cuddihy RM, Wesley D, Morgan B. Continuous glucose monitoring reveals different glycemic responses of moderate - vs high-carbohydrate lunch meals in people with type 2 diabetes. J Am Diet Assoc 2010;110:1912-5.
102. Pearce KL, Noakes M, Keogh J, Clifton PM. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. Am J Clin Nutr 2008;87:638-44. (Pubitemid 351364545)
103. Gerhard GT, Ahmann A, Meeuws K, McMurry MP, Duell PB, Connor WE. Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in type 2 diabetes. Am J Clin Nutr 2004;80:668-73. (Pubitemid 41115532)
104. Tapsell LC, Gillen LJ, Patch CS, Batterham M, Owen A, Baré M, et al. Including walnuts in a low-fat/modifiedfat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care 2004;27:2777-83. (Pubitemid 39565036)
105. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 2006;84:328-35. (Pubitemid 44699141)
106. American Heart Association guidelines. Circulation 2008;117:1610-9.
107. American Association of Clinical Endocrinologists & ADA Consensus statement. Diabetes Care 2009;32:119-31.
108. American Diabetes Association Recommendations. Diabetes Care 2011;34(Suppl. 1):S45-6.
109. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Unrecognized diabetes among hospitalized patients. Diabetes Care 1998;21:246-9. (Pubitemid 28079432)
110. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. J Hosp Med 2007;2: 314-23. (Pubitemid 350020008)
111. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003;138:161-7. (Pubitemid 36231621)
112. Lauster CD, Gibson JM, DiNella JV, DiNardo M, Korytkowski MT, Donihi AC. Implementation of standardized instructions for insulin at hospital discharge. J Hosp Med 2009;4: E41-2.
113. Wood ER. Evaluation of a hospital-based education program for patients with diabetes. J Am Diet Assoc 1989;89: 354-8. (Pubitemid 19090090)
114. Mühlhauser I, Bruckner I, Berger M, Cheta D, Jörgens V, Ionescu-Trgoviste C, et al. Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest- Düsseldorf Study. Diabetologia 1987;30:681-90. (Pubitemid 17155773)
115. Feddersen E, Lockwood DH. An inpatient diabetes educators impact on length of hospital stay. Diabetes Educ 1994;20:125-8.
116. Roman SH, Chassin MR. Windows of opportunity to improve diabetes care when patients with diabetes are hospitalized for other conditions. Diabetes Care 2001;24:1371-6. (Pubitemid 33716423)
117. Koproski J, Pretto Z, Poretsky L. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care 1997;20:1553-5. (Pubitemid 27415033)
118. Levetan CS, Passaro MD, Jablonski KA, Ratner RE. Effect of physician specialty on outcomes in diabetic ketoacidosis. Diabetes Care 1999;22:1790-5. (Pubitemid 29521863)
119. Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med 1995;99:22-8.
120. Avanzini F, Marelli G, Donzelli W, Busi G, Carbone S, Bellato L, et al. Transition from intravenous to subcutaneous insulin: effectiveness and safety of a standardized protocol and predictors of outcome in patients with acute coronary syndrome. Diabetes Care 2011;34:1445-50.